Paper Details

  1. Home
  2. Paper Details

[The use of bismuth tripotassium dicitrate (De-Nol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea].

Author: AgafonovaN A, AldiiarovaM A, D'iachkoavaA V, DavletshinaI V, GioevaI Z, IakovenkoA V, IakovenkoE P, IvanovA N, KolganovaA V, NazarbekovaR S, OvchinnikovaN I, Pokhal'skaiaO Iu, PopovaE V, PrianishnikovaA S

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study found that bismuth tripotassium dicitrate (De-nol) was effective for treating diarrhea-dominant irritable bowel syndrome (IBS) when used with a spasmolytic medication. After 3 weeks of treatment, 90% of the De-nol group and 60% of the control group had no abdominal pain. The De-nol group also saw improvements in bloating, diarrhea, and intestinal bacterial overgrowth. De-nol was found to be effective in resolving inflammation and restoring normal gut bacteria.
Paper Details　
Original Abstract of the Article :
The aim of the study was to assess the expediency of prescription and efficiency of bismuth tri-potassium di-citrate in different therapeutic schemes for the management of irritable bowel syndrome (IBS) dominated by diarrhea. The open prospective study of de-nol efficacy and safety included 30 patie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/19069460

データ提供：米国国立医学図書館（NLM）

Irritable Bowel Syndrome with Diarrhea: A Desert of Digestive Distress

Irritable bowel syndrome with diarrhea (IBS-D), like a desert mirage, can be a source of frustration and discomfort. This research explores the potential benefits of bismuth tripotassium dicitrate (De-Nol) in managing IBS-D, examining its effectiveness in reducing symptoms and restoring normal intestinal function.

De-Nol: A Desert Oasis of Relief

The study found that De-Nol, in combination with a spasmolytic agent, was effective in reducing abdominal pain, diarrhea, and meteorism in patients with IBS-D. It also demonstrated a significant impact on restoring normal intestinal microflora and reducing inflammation.

IBS-D: Managing the Desert Mirage

IBS-D can significantly impact quality of life, making it difficult to enjoy daily activities. This research suggests that De-Nol may offer a valuable therapeutic option for managing IBS-D, potentially improving patient comfort and well-being.

Dr. Camel's Conclusion

This research provides encouraging evidence for the effectiveness of De-Nol in treating IBS-D. It highlights the importance of addressing the underlying factors contributing to IBS-D, including intestinal inflammation and dysbiosis, to develop effective treatment strategies for this common gastrointestinal disorder.
Date :
  1. Date Completed 2009-01-09
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

19069460

DOI: Digital Object Identifier

19069460

Related Literature

Article Analysis
・Effective treatment of irritable bowel syndrome
SNS
PICO Info
in preparation
Languages

Russian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.